Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 27, 2018
- Accepted in final form May 7, 2019
- First Published July 16, 2019.
Author Disclosures
- Chenyu Wang, PhD,
- Michael H. Barnett, PhD,
- Con Yiannikas, FRACP,
- Joshua Barton, FRACP,
- John Parratt, FRACP,
- Yuyi You, PhD,
- Stuart L. Graham, PhD and
- Alexander Klistorner, PhD
- Chenyu Wang, PhD,
NONE
NONE
Novartis, Travel support attending ECTRIMS2018 conference
NONE
NONE
NONE
Sydney Neuroimaging Analysis Centre, Director of Operations, 0.4 years
NONE
NONE
NONE
NONE
NONE
Multiple Sclerosis Research Australia, 18-0461, MSRA fellowship, 3 years
NONE
Nerve Research Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Michael H. Barnett, PhD,
1.Novartis, scientific advisory board 2.Genzyme-Sanofi, scientific advisory board
NONE
1. Teva, Conference Travel (2016 ECTRIMS)
NONE
NONE
NONE
NONE
1. Sydney Neuroimaging Analysis Centre
NONE
Consultant, Medical Safety Systems / RxMx.
NONE
1. Novartis, Research Grant support 2. Genzyme-Sanofi, Research Grant Support 3. Bio-CSL, Research Grant Support 4. Biogen, Research Grant Support
1. Australian Government, CRC-P Grant: "New Smarts for the Medical Imaging Industry", Partner Investigator, 2018-2021
1. MS Research Australia, Project Grant: "Does somatic mutation in the brain drive progressive MS?", Co- Investigator 2018-2021 2. MS Research Australia, Project Grant: "Understanding the induction of disease quiescence by immunomodulating drugs in multiple sclerosis", Co-Investigator, 2018-2021. 3. The University of Sydney. SOAR Research accelerator Fellowship, CI, 2018-2019.
Nerve Research Foundation, The University of Sydney
NONE
NONE
NONE
NONE
NONE
NONE
- Con Yiannikas, FRACP,
Teva advisory board for migraine.
NONE
Commercial- Ipsen-Travel to Int Movement disorders meeting 2018 Biogen speaker 2019 CSL speaker 2019
NONE
NONE
NONE
NONE
Consultant-Allergan, Ipsen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joshua Barton, FRACP,
NONE
NONE
(1) Teva, educational travel support (2) Novartis, educational travel support (3) Sanofi-Genzyme, educational travel support, speaker honoraria (4) Merck, educational travel support, speaker honoraria (5) Biogen, educational travel support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Multiple Sclerosis Research Australia- postgraduate scholarship
NONE
NONE
NONE
NONE
NONE
NONE
- John Parratt, FRACP,
1. Commercial - Genzyme scientific advisory board 2. Commercial - Novartis scientific advisory board 3. Biogen advisory board
NONE
1. Commercial - Honoraria from Biogen for educational meetings 2. Commercial - Honoraria from Genzyme/Sanofi for educational meetings 3. Commercial - Honoraria from Merck Serono for educational meetings.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Multiple sclerosis research Australia Neil and Norma Hill inaugural junior practitioner fellowship
NONE
NONE
NONE
NONE
NONE
NONE
- Yuyi You, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Health and Medical Research Council (NHMRC), #1089853, CI, 2015-2018 (2) The Ophthalmic Research Institute of Australia (ORIA), CI, 2017,2019 (3) Sydney Medical School, CI, 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stuart L. Graham, PhD and
(1)Allergan Australia
NONE
(1) Allergan Australia - conference support 2)Novartis Australia - invited lecturer
(1)Clin Exp Ophthalmol - Glaucoma Section editor
(1)US Patent for multifocal VEP electrode positioning and signal scaling
NONE
NONE
NONE
NONE
NONE
NONE
(1)Novartis - research support (2)Allergan Australia - research fellowship support
(1 ) NHMRC grants CIA x2 Perpetual Hillcrest Foundation grant CIA Ophthalmic Research Institute Australia Grant CIA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alexander Klistorner, PhD
NONE
NONE
NONE
NONE
1. "Electrophysiological visual field measurement" Klistorner and Graham 1999, PCT/AU99/00340. 2. "Method and apparatus for objective electrophysiological assessment of visual function" Klistorner and Graham 2001, PCT/AU01/00423. 3. ?Stimulus Method for Multifocal Visual Evoked Potential? Klistorner and Graham (Australian Patent Application No 2007900803). 4. ?Flexible electrode assembly and apparatus for measuring electrophysiological signals? Cheng, Klistorner, Graham (Australian Provisional Patent # 2006904755). 5. ?Apparatus for measuring electrophysiological signals? Cheng, Klistorner, Dyer - Australian Design No. 310666. 6. ? Flexible printed circuit board electrode assembly? Cheng, Klistorner, Dyer - Australian Design No. 311943.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Sydney University Foundation for Medical Research. 2. Sydney eye hospital foundation
NONE
NONE
NONE
NONE
NONE
NONE
- From the Brain and Mind Centre (C.W., M.H.B., J.B.), Sydney Medical School, University of Sydney; Sydney Neuroimaging Analysis Centre (C.W., M.H.B.); Royal North Shore Hospital (C.Y., J.P.); Save Sight Institute (Y.Y., A.K.), Sydney Medical School, University of Sydney; and Faculty of Medicine and Health Sciences (S.L.G., A.K.), Macquarie University, Sydney, NSW, Australia.
- Correspondence
Dr. Klistorner sasha{at}eye.usyd.edu.au
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imagingSvetlana Bezukladova, Jouni Tuisku, Markus Matilainen et al.Neurology: Neuroimmunology & Neuroinflammation, March 02, 2020 -
Article
High serum neurofilament associates with diffuse white matter damage in MSMaija Saraste, Svetlana Bezukladova, Markus Matilainen et al.Neurology: Neuroimmunology & Neuroinflammation, December 08, 2020 -
Article
Natalizumab in progressive MSResults of an open-label, phase 2A, proof-of-concept trialJeppe Romme Christensen, Rikke Ratzer, Lars Börnsen et al.Neurology, March 28, 2014 -
Article
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H. Miller, Robert J. Fox, J. Theodore Phillips et al.Neurology, February 13, 2015